Browse Newsroom

InsuLife further strengthens its Board of Directors

July 14, 2022

We are excited to announce that at our June General Meeting, InsuLife’s Board of Directors was further strengthened by the appointment of Anne Waaler and Kari Struknes as Directors. “Anne and Kari bring solid pharmaceutical experience and expertise in the important fields of clinical development and regulatory and quality assurance, which are at the heart of InsuLife’s focused activities. We welcome Anne and Kari to our Board of Directors as the Company is now entering into its next phase of development, says Eric Cameron, Chairman in InsuLife.

Anne Waaler brings more than 35 years in management positions in the pharmaceutical industry and brings experience from clinical development and strategic marketing in Nycomed, Amersham, GE and Medistim. She is a pharmacist from the University of Oslo with an MBA from BI and ESCP-EAP in Paris.

Kari Struknes, PhD, has experience as a manager in the Regulatory Department of the Norwegian Medicines Agency and has had increasing responsibility in managerial positions within regulatory and quality assurance at GSK. Now she is ‘Regional QRM Director, Europe, EM & Intercontinental – Global Regulatory & Quality Assurance’. She is a biochemist with a PhD from the University of Oslo.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved